Shimon Slavin

14 Weizman St
Tel Aviv, TA 64238, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Effects of Small Extracellular Vesicles Derived From Mesenchymal Stromal Cells on Acute Kidney Injury: A Rat Ischemia-Reperfusion Model.

Effects of Small Extracellular Vesicles Derived From Mesenchymal Stromal Cells on Acute Kidney Injury: A Rat Ischemia-Reperfusion Model.

Journal: Cureus

Published: May 17, 2025

Cell-mediated immunotherapy: A new frontier in preventing disease progression and treating drug-resistant cancer.

Cell-mediated immunotherapy: A new frontier in preventing disease progression and treating drug-resistant cancer.

Journal: Med (New York, N.Y.)

Published: November 04, 2024

Immunotherapy with cure potential of multi-drug resistant hematologic malignancies using IL-2 preactivated intentionally mismatched donor lymphocyte.

Immunotherapy with cure potential of multi-drug resistant hematologic malignancies using IL-2 preactivated intentionally mismatched donor lymphocyte.

Journal: Journal of cancer research and clinical oncology

Published: February 20, 2023

A Clinically Validated, Broadly Active, Oral Viral Superinfection Therapy Could Mitigate Symptoms in Early-stage COVID-19 Patients.

A Clinically Validated, Broadly Active, Oral Viral Superinfection Therapy Could Mitigate Symptoms in Early-stage COVID-19 Patients.

Journal: Infectious disorders drug targets

Published: November 17, 2021

Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies.

Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies.

Journal: Cancer immunology, immunotherapy : CII

Published: November 20, 2019

Human mesenchymal stromal cells ameliorate complement induced inflammatory cascade and improve renal functions in a rat model of ischemia-reperfusion induced acute kidney injury.

Human mesenchymal stromal cells ameliorate complement induced inflammatory cascade and improve renal functions in a rat model of ischemia-reperfusion induced acute kidney injury.

Journal: PloS one

Published: March 11, 2019

Human Peripheral Blood Mononuclear Cells Incubated in Vasculogenic Conditioning Medium Dramatically Improve Ischemia/Reperfusion Acute Kidney Injury in Mice.

Human Peripheral Blood Mononuclear Cells Incubated in Vasculogenic Conditioning Medium Dramatically Improve Ischemia/Reperfusion Acute Kidney Injury in Mice.

Journal: Cell transplantation

Published: May 09, 2018

Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.

Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.

Journal: Stem cell research & therapy

Published: July 01, 2016

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Journal: Blood

Published: September 24, 2015

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.

Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Published: July 01, 2015

Transplant of ex vivo incubated bone marrow with rIL -7 for the enhancement of immuno-hematopoietic reconstitution.

Transplant of ex vivo incubated bone marrow with rIL -7 for the enhancement of immuno-hematopoietic reconstitution.

Journal: Leukemia & lymphoma

Published: May 31, 2015

Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity.

Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity.

Journal: Pharmacological research

Published: October 24, 2013

Showing 1-12 of 21

Last Updated: 09/26/2026